Nothing Special   »   [go: up one dir, main page]

BR112019008241A2 - tratamento do prurigo nodular - Google Patents

tratamento do prurigo nodular

Info

Publication number
BR112019008241A2
BR112019008241A2 BR112019008241A BR112019008241A BR112019008241A2 BR 112019008241 A2 BR112019008241 A2 BR 112019008241A2 BR 112019008241 A BR112019008241 A BR 112019008241A BR 112019008241 A BR112019008241 A BR 112019008241A BR 112019008241 A2 BR112019008241 A2 BR 112019008241A2
Authority
BR
Brazil
Prior art keywords
treatment
nodular prurigo
prurigo
nodular
patient
Prior art date
Application number
BR112019008241A
Other languages
English (en)
Inventor
Hawi Amale
Good Jennifer
Sciascia Thomas
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of BR112019008241A2 publication Critical patent/BR112019008241A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a métodos para tratamento do prurigo nodular com composições antipruríticas, em que o método proporciona um efeito terapêutico em um paciente.
BR112019008241A 2016-10-25 2017-10-25 tratamento do prurigo nodular BR112019008241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662412578P 2016-10-25 2016-10-25
PCT/US2017/058294 WO2018081273A1 (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Publications (1)

Publication Number Publication Date
BR112019008241A2 true BR112019008241A2 (pt) 2019-07-16

Family

ID=62025443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008241A BR112019008241A2 (pt) 2016-10-25 2017-10-25 tratamento do prurigo nodular

Country Status (11)

Country Link
US (3) US20180125840A1 (pt)
EP (1) EP3532061A4 (pt)
JP (2) JP2019532112A (pt)
KR (1) KR102696347B1 (pt)
CN (1) CN109862895A (pt)
AU (1) AU2017350852A1 (pt)
BR (1) BR112019008241A2 (pt)
CA (1) CA3038544A1 (pt)
MX (1) MX2019004804A (pt)
NZ (1) NZ751972A (pt)
WO (1) WO2018081273A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105680A1 (en) * 2018-07-11 2020-01-16 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
EP4087569A4 (en) * 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
WO2023150579A2 (en) * 2022-02-01 2023-08-10 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing nalbuphine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375287B2 (en) * 2008-01-29 2016-06-28 Covidien Lp Target identification tool for intra-body localization
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
RU2015128265A (ru) * 2012-12-14 2017-01-25 Треви Терапьютикс, Инк. Способы лечения зуда
US20150359789A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Also Published As

Publication number Publication date
EP3532061A1 (en) 2019-09-04
CN109862895A (zh) 2019-06-07
JP2022191405A (ja) 2022-12-27
US20230338367A1 (en) 2023-10-26
EP3532061A4 (en) 2020-07-08
JP2019532112A (ja) 2019-11-07
NZ751972A (en) 2022-12-23
KR20190073385A (ko) 2019-06-26
CA3038544A1 (en) 2018-05-03
KR102696347B1 (ko) 2024-08-19
US20220347171A1 (en) 2022-11-03
WO2018081273A1 (en) 2018-05-03
AU2017350852A1 (en) 2019-04-11
MX2019004804A (es) 2019-08-22
US20180125840A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112016019825A2 (pt) anticorpos do fator bb do complemento
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]